TechNavio’s analysts forecast the Global Lung Cancer Therapeutics market to grow at a CAGR of 13.26 percent over the period 2012-2016. One of the key factors contributing to this market growth is the significant growth of the Lung Cancer Therapeutics market in the US. The Global Lung Cancer Therapeutics market has also been witnessing an increase in the number of M&As. However, the adversative side effects of lung cancer therapeutic drugs could pose a challenge to the growth of this market.... Research Beam Model: Research Beam Product ID: 16310 2500 USD New
Global Lung Cancer Therapeutics Market 2012-2016
 
 

Global Lung Cancer Therapeutics Market 2012-2016

  • Category : Healthcare
  • Published On : January   2013
  • Pages : 55
  • Publisher : Technavio
 
 
 

TechNavio’s analysts forecast the Global Lung Cancer Therapeutics market to grow at a CAGR of 13.26 percent over the period 2012-2016. One of the key factors contributing to this market growth is the significant growth of the Lung Cancer Therapeutics market in the US. The Global Lung Cancer Therapeutics market has also been witnessing an increase in the number of M&As. However, the adversative side effects of lung cancer therapeutic drugs could pose a challenge to the growth of this market. 



TechNavio’s report, the Global Lung Cancer Therapeutics Market 2012-2016, has been prepared based on an in-depth analysis of the market with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Lung Cancer Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.



The key vendors dominating this market space are AstraZeneca plc, Bristol-Myers Squibb Co., Eli Lilly and Co., GlaxoSmithKline plc, Hoffmann-La Roche Ltd., and Novartis AG. 



The other vendors mentioned in the report are Ambit Biosciences Inc., ARIAD Pharmaceuticals Inc., Biogen Idec Inc., Cephalon Inc., Clavis Pharma ASA, Eisai Co. Ltd., ERYtech Pharma SA, Genmab A/S, Genzyme Corp., Pfizer Inc., Sunesis Pharmaceuticals Inc., Talon Therapeutics Inc., and Teva Pharmaceutical Industries Ltd.



Key questions answered in this report:

What will the market size be in 2016 and what will the growth rate be?

What are the key market trends?

What is driving this market?

What are the challenges to market growth?

Who are the key vendors in this market space?

What are the market opportunities and threats faced by the key vendors?

What are the strengths and weaknesses of the key vendors?


01. Executive Summary

02. Introduction

03. Market Coverage


Market Overview

Key Products

04. Market Landscape

Market Size

Market Forecast

04.1 Five Forces Analysis

05. Geographical Segmentation

06. Key Leading Countries

US

Germany

Japan

07. Rate of Incidence and Prevalence

08. Vendor Landscape

09. Buying Criteria

10. Market Growth Drivers

11. Drivers and their Impact

12. Market Challenges

13. Impact of Drivers and Challenges

14. Market Trends

15. Key Vendor Analysis


15.1 Hoffmann-La Roche Ltd.

Business Overview

Key Information

SWOT Analysis

15.2 Eli Lilly and Co.

Business Overview

Key Information

SWOT Analysis

15.3 Sanofi S.A.

Business Overview

Key Information

SWOT Analysis

15.4 Bristol-Myers Squibb Co.

Business Overview

Key Information

SWOT Analysis

15.5 AstraZeneca plc

Business Overview

Key Information

SWOT Analysis

15.6 Novartis AG

Business Overview

Key Information

SWOT Analysis

15.7 GlaxoSmithKline plc

Business Overview

Key Information

SWOT Analysis

16. Other Reports in this Series



List of Exhibits:

Exhibit 1: Global Lung Cancer Therapeutics Market 2012–2016 (US$ billion)

Exhibit 2: Global Lung Cancer Therapeutics Market by Geographical Segmentation 2012

Exhibit 3: Global Lung Cancer Therapeutics Market by Vendor Segmentation 2012

Exhibit 4: Global Lung Cancer Therapeutics Market by Leading Drugs Segmentation 2012

Exhibit 5: Business Segmentation of Hoffmann-La Roche Ltd.

Exhibit 6: Business Segmentation of Eli Lilly and Co.

Exhibit 7: Business Segmentation of Sanofi S.A.

Exhibit 8: Business Segmentation of Bristol-Myers Squibb Co.

Exhibit 9: Business Segmentation of AstraZeneca plc

Exhibit 10: Business Segmentation of Novartis AG

Exhibit 11: Business Segmentation of GlaxoSmithKline plc



PURCHASE OPTIONS
 
 
 

How can we help you?

Contact us at the Consulting WP office nearest to you or submit a business inquiry online.


  Contact
 

Subscribe to Our Newsletter

 
 

Related Reports

REQUEST SAMPLE    ASK FOR DISCOUNT